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Autologous (auto-) and allogeneic (allo-) hematopoietic cell transplantation (HCT) are accepted treatment modali-
ties in contemporary treatment algorithms for mantle cell lymphoma (MCL). Chimeric antigen receptor (CAR) T
cell therapy recently received approval for MCL; however, its exact place and sequence in relation to HCT remain
unclear. The American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow
Transplant Research, and the European Society for Blood and Marrow Transplantation jointly convened an expert
panel to formulate consensus recommendations for role, timing, and sequencing of auto-HCT, allo-HCT, and CAR T
cell therapy for patients with newly diagnosed and relapsed/refractory (R/R) MCL. The RAND-modified Delphi
method was used to generate consensus statements. Seventeen consensus statements were generated, with a few
key statements as follows: in the first line setting, auto-HCT consolidation represents standard of care in eligible
patients, whereas there is no clear role of allo-HCT or CAR T cell therapy outside of clinical trials. In the R/R setting,
the preferential option is CAR T cell therapy, especially in patients with MCL failing or intolerant to at least one
Bruton’s tyrosine kinase inhibitor, while allo-HCT is recommended if CAR T cell therapy fails or is infeasible. Sev-
eral recommendations were based on expert opinion, where the panel developed consensus statements for
important real-world clinical scenarios to guide clinical practice. In the absence of contemporary evidence-based
data, the panel found RAND-modified Delphi methodology effective in providing a formal framework for develop-
ing consensus recommendations for the timing and sequence of cellular therapies for MCL.
© 2021 Dr. Mehdi Hamadani. Published by Elsevier Inc. on behalf of The American Society for Transplantation and








Mantle cell lymphoma (MCL) is a B cell lymphoma that dis-
plays significant clinical and molecular heterogeneity [1]. In
most cases, it follows an aggressive clinical course; however, a
subset of patients can have indolent disease [2]. Similarly, the
management of MCL varies greatly in clinical practice in the
United States and worldwide [3,4]. This variability applies to
both the frontline and relapsed/refractory (R/R) settings [5].
Pertaining to frontline therapy, some advocate induction che-
moimmunotherapy followed by high-dose therapy (HDT) and
then autologous hematopoietic cell transplantation (auto-
HCT) consolidation, whereas others prefer combination che-
moimmunotherapy regimens alone without subsequent HDT
consolidation. Treatment strategies are even more discordant
in the presence of high-risk features, such as TP53 alterations
and a high proliferation index [6-8]. In the R/R setting, there is
also variability in practice, which is made even more complex
by the advent of newer treatment modalities, such as Bruton’s
tyrosine kinase (BTK) inhibitors [9], lenalidomide, and chime-
ric antigen receptor (CAR) T cell therapy [10].
Auto-HCT consolidation has been used for over 20 years in
the management of MCL patients [11,12], and is associated
with improved progression-free survival (PFS) and potentially
overall survival (OS) following conventional chemoimmuno-
therapy in both prospective and retrospective studies [11-14].
However, it is less clear whether auto-HCT has a benefit fol-
lowing more intensive chemoimmunotherapy, such as rituxi-
mab-hyper-CVAD/cytarabine/methotrexate [15]. Allo-HCT is a
potentially curative modality for MCL [12,16]; however, with a
1-year treatment-related mortality ranging from 10% to 20%
and the additional risk of chronic graft-versus-host disease
(GVHD), allo-HCT generally has been reserved for the R/R set-
ting [3,17].
There have been recent important advances in MCL ther-
apy, including the demonstration of a survival benefit with rit-
uximab maintenance following auto-HCT [18], the advent of
first- and second-generation BTK inhibitors for R/R MCL [19],
and the recent approval of the first commercially availableCAR T cell therapy (brexucabtagene autoleucel) for MCL [10].
For brexucabtagene autoleucel, the reported objective and
complete response rates were 93% and 67%, respectively, with
durable remission seen in >50% of patients. Importantly,
although this registration trial exclusively studied MCL
patients who had been previously treated with BTK inhibitor
therapy, US regulatory approval provides an indication for all
patients with R/R MCL regardless of previous exposure to a
BTK inhibitor.
Given these novel treatment options, guidance on the con-
temporary role, optimal timing, and sequencing of cellular
therapies in MCL is warranted. Clinical practice recommenda-
tions addressing areas of clinical ambiguity not only can aid
the treating transplantation and cellular therapy physicians,
but also can inform lymphoma experts’ and community hema-
tologists’ practice for referring these patients to transplanta-
tion and cellular therapy programs. The American Society of
Transplantation and Cellular Therapy (ASTCT), Center of Inter-
national Blood and Marrow Transplant Research (CIBMTR),
and European Society for Blood and Marrow Transplantation
(EBMT) undertook a joint project to formulate consensus rec-
ommendations regarding the role, timing, and sequencing of
auto-HCT, allo-HCT, and CAR T cell therapy for patients with
newly diagnosed and R/R MCL.
METHODS
Panel Composition
The development of practice recommendations was approved by the
ASTCT, CIBMTR, and EBMT, the 3 leading international organizations in the
field of HCT and cellular therapies. As an initial step, a Steering Committee
was formed comprising 6 members including 2 project leaders/coordinators;
1 representative each from the ASTCT, EBMT, and CIBMTR; and an indepen-
dent methodologist with expertise in systematic reviews, meta-analysis, and
the RAND-modified Delphi method. The Steering Committee was responsible
for drafting the protocol, producing the initial draft of the consensus state-
ments based on clinical expertise and clinical practice considerations, and
setting up the expert panel [20]. The aim was to put together an expert panel
with a balanced distribution of MCL and cellular therapy and transplant
experts, to have broad expertise, and to cover a wide spectrum of views while
keeping administrative efforts manageable, as previously recommended
[21,22]. The panel of experts consisted of physicians with a diverse
Table 1
Steps Involved in the RAND-modified Delphi Methodology
Step Representation Description Method
Concept development and
approval
Steering Committee Approved and endorsed by the CIBMTR LYWC in Feb-
ruary 2020, the EBMT LWP in March 2020, and the
ASTCT CoPG in March 2020
In-person meeting/ teleconference
Protocol development Steering Committee Protocol development according to the modified Del-
phi method; identify and invite potential members of
the Consensus Panel, including academic experts plus
a community practice representative
Email and electronic communication
BD&S survey Consensus Panel Obtain demographic details of the participants and
determine the clinical scope of the project, with rat-
ings along with written feedback, June 2020*
Online survey (100% panel response rate)
Review of results of BD&S survey Steering Committee Results complied by the Steering Committee and
shared with the Consensus Panel
Email
Consensus Panel questions pertaining to sequence of cellular therapy
(including auto HCT, allo HCT and CAR T cell) and
practice scenarios generated for the first voting sur-
vey (Steering Committee)
Email
First voting survey Consensus Panel Rate clinical practice recommendation statements on
a Likert scale, August 2020
Online survey (100% panel response rate)
Review of results of first voting
survey
Steering Committee Results complied and reviewed by the Steering
Committee
Email
Consensus Panel Results shared with the Consensus Panel in Septem-
ber 2020
Email
Discussion and revision of
recommendations
Consensus Panel Presentation of results of the first voting survey by
the Steering Committee
Virtual (video) conferencey
Group discussion on the ranking of clinical practice
recommendation statements and modification of
statements not achieving consensus threshold, Octo-
ber 2020
Second voting survey Consensus Panel Revised clinical practice recommendation statements
sent to the Consensus Panel for voting, November
2020
Online survey (100% panel response rate)




Ratings are accepted if a consensus is reached based
on predefined threshold. If a consensus is not
reached, statements were noted as “consensus could
not be reached.” Results compiled in a first-draft
manuscript written by the Steering Committee and
shared with the Consensus Panel for review and
editing.
Email
CIBMTR LYWC indicates Center for International Blood and Marrow Transplant Registry Lymphoma Working Committee; EBMT LWP, European Group of Blood and
Marrow Transplantation LymphomaWorking Party; ASTCT CoPG , American Society of Transplantation and Cellular Therapy Committee on Practice Guidelines.
* The Steering Committee comprised 6 members, including 2 project leaders/coordinators, 1 statistical expert (independent nonvoting member), and 1 member
each representing the CIBMTR, EBMT, and ASTCT. The Consensus Panel (n = 33) comprised 5 Steering Committee members (all but the statistical expert), 27 academic
experts, and 1 community representative.
y Attended by 26 members (4 persons provided their recommendation via review of survey questions, review of video recording of the meeting and were not pres-
ent during the meeting) of the Consensus Panel via teleconference held on 10/30/20.
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their track records of peer-reviewed publications, leadership on clinical trials
relevant to the consensus project, and involvement in national and interna-
tional lymphoma or transplantation organizations. In addition, the panel
included a physician representing a community-based practice (N.G.), as pre-
viously recommended [20]. The final Consensus Panel consisted of 33 physi-
cians and investigators, including all members of the Steering Committee
except the (nonclinical) independent methodologist (A.K.), who did not vote
on the recommendations.
Consensus Methodology
The RAND-modified Delphi method was used to generate consensus state-
ments addressing the role, timing, and sequence of HCT and CAR T cell thera-
pies in patients with newly diagnosed and R/R MCL. In the Delphi method, the
participants rate the statements anonymously in at least 2 rounds of evalua-
tions. In the modified version of the Delphi method, a face-to-face meeting
with presentation of the results precedes the second round of rating [20-22].
Owing to the ongoing COVID-19 pandemic, a virtual platform (Zoom, San Jose,
CA) was used in lieu of a face-to-face meeting. Details of the systematic step-
by-step approach used in this project are provided in Table 1.
After Consensus Panel selection, a baseline demographics and scope
(BD&S) survey was developed to determine the scope of the project. Partici-
pants were invited to submit their suggestions regarding the scope of the
consensus project and provide input about the clinical issues relevant toclinical practice (details in Supplementary Material). Once the scope of the
consensus project was finalized, the Steering Committee formulated prelimi-
nary consensus statements based on expert opinion for the first round of vot-
ing (details in Supplementary Tables S1 and S2).
The first voting survey included 19 consensus statements. Consensus
Panel members rated each statement electronically. The Steering Committee
methodologist analyzed and summarized the results while keeping the indi-
vidual ratings anonymous. A specific proposed statement was defined as hav-
ing achieved formal consensus if 75% of the panel members voted to agree
with it. The results of the first voting survey, along with the statements not
reaching the threshold of consensus, were presented at the virtual teleconfer-
ence of the panel members. Consensus statements that met the predefined
criteria for formal consensus were recommended for approval. Statements
that failed to achieve predefined criteria for consensus were discussed during
the virtual meeting, and based on the discussions, were modified for revoting
or dropped. The second voting survey was sent to all Consensus Panel mem-
bers for rating the reformulated or newly added statements.
All surveys were administered online using Qualtrics software (Qualtrics,
Provo, UT), and results were reviewed and collated independently by the
methodological expert. At each step of the process, the electronic survey also
allowed the participating members to provide written feedback and com-
ments about each statement. Collated results were shared via email with the
Consensus Panel members in real time after each step was completed to
ensure transparency of the process. The final consensus statements were
Table 2
Demographic Information of Consensus Panel Members (N = 33)
Member Demographics No. (%)
Male sex 24 (72.7)
Female sex 9 (27.3)
Practice setting Academic 31 (93.9)
Community 2 (6.1)





Description of clinical practice Nontransplantation lymphoma practice 3 (9.0)
Primarily HCT and/or cell therapy practice 5 (15.2)
Combined lymphoma and HCT/cell therapy practice 25 (75.8)
Region of practice* North America 26 (78.8)
Europe 6 (18.2)
Middle East 1 (3.0)
Estimated number of newly diagnosed lymphoma patients





Estimated number of mantle cell lymphoma patients seen





Estimated annual transplant volume at respective programs














Estimated annual autologous HCT performed at respective







Estimated annual CAR T cell therapies performed at respec-





Statistical expert A.K. did not participate in the voting process.
* Countries represented include: United States, n = 26; Germany, n = 2; United Kingdom, n = 1; Spain, n = 1; Italy, n = 1; Sweden, n = 1; Saudi Arabia, n = 1.
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to the Agency of Healthcare Research and Quality grading system [23].
RESULTS
Member Participation
Table 2 summarizes the baseline characteristics of Consen-
sus Panel members. Included were transplantation and cellular
therapy physicians (>75% of practice time in HCT), non-cellu-
lar therapy academic physicians, mixed practitioners, and a
community-based practitioner. A mixed practice was defined
as practitioners devoting approximately 50% of their clinical
time to HCT and the other 50% to non-cellular therapy-related
lymphoma treatment. In general, panelist participation andresponse rates were excellent. During the voting process, 100%
(n = 33) panel member participation was noted for the BD&S,
first voting, and second voting surveys. The virtual meeting
was attended by 26 members, including 4 members who pro-
vided their absentee vote by providing written feedback in
advance of (n = 1) or after the meeting, after reviewing the
video recordings of the teleconference (n = 3).
First Voting Survey
The first voting survey consisted of 19 statements specific
to the role of auto-HCT in eligible newly diagnosed MCL
patients (6 statements) and R/R MCL patients (2 statements),
allo-HCT for newly diagnosed MCL patients (3 statements),
Table 3
Final Clinical Practice Guidelines Consensus Statements for Transplantation and CAR T Cell Treatments in the First-Line Setting for MCL
Consensus Statement Grading of Recommendations* Panelists in Agreement, %
1. The panel recommends autologous HCT as consolidation therapy in eligible, newly
diagnosed MCL patients (without TP53 mutation or biallelic deletion) in complete
remission or partial remission after first-line therapies.
A 87.9
2. The panel does not recommend autologous transplantation as consolidation therapy
in MCL patients with disease not responsive to most recent antilymphoma therapy.
B 100
3. The panel does not recommend using measurable residual disease (MRD) testing to
guide use of autologous transplantation consolidation after first-line therapies in MCL
outside the setting of a clinical trial.
C 100
4. The panel does not recommend using MIPI or MIPI-c prognostic score as a criterion
determining use of autologous transplantation as consolidation therapy in eligible
newly diagnosed MCL patients in first complete remission or partial remission after
first-line therapies.
C 100
5. The panel does not recommend allogeneic transplantation consolidation in MCL
patients (without TP53 mutation or biallelic deletion), achieving a complete or partial
remission after first-line therapies.
B 97
6. The panel does not recommend consolidation with CAR T cell therapy in MCL
patients achieving a complete or partial remission after first-line therapies outside the
setting of a clinical trial.
C 100
7. If a TP53 mutation (or biallelic deletion) is present, the panel recognizes that out-
comes are poor for MCL patients in complete or partial remission after first-line thera-
pies who then undergo autologous transplantation. However, no specific alternative
strategy has yet been shown to improve outcomes in such patients. Therefore, the
panel recommends considering autologous transplantation consolidation as well as
alternative consolidation strategies (eg, CAR T cell therapy or allogeneic transplanta-
tion), ideally in the context of a clinical trial, for such patients.
C 100
PET/CT indicates positron emission tomography/computed tomography.
* Agency of Healthcare Research and Quality grading of recommendations based on level of evidence [15]:
A: There is good research-based evidence to support the recommendation.
B: There is fair research-based evidence to support the recommendation.
C: The recommendation is based on expert opinion and panel consensus.
X: There is evidence of harm from this intervention.
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statements). All but 5 statements achieved consensus by pre-
defined criteria (Supplementary Table S1). The results of the
first voting survey were shared electronically with all panel
members. The 5 statements not achieving consensus (<75%
agreement) during the previous voting process were reviewed
by the Steering Committee and presented to the Consensus
Panel members at the virtual video conference. The ensuing
discussion resulted in one statement regarding auto-HCT being
abandoned and all other statements being revised. A total of 3
statements were proposed (2 reformulated statements and 1
merged statement) for the second voting survey. Supplemen-
tary Table S2 presents the outcomes of the virtual video con-
ference.
Second Voting Survey
All statements included in the second voting survey (2
reformulated statements and 1 merged statement) met the
predefined criteria for consensus (Supplementary Table S2).
The final consensus recommendations on auto-HCT, allo-HCT,
and CAR T cell therapy for upfront and relapsed MCL consisting
of 17 consensus statements are provided in Tables 3 and 4.
DISCUSSION
In this project, a broadly representative panel of lym-
phoma, transplantation, and cellular therapy experts with
diverse practice experience and geographical representation,
endorsed by the ASTCT, EBMT, and CIBMTR, was formed to
provide consensus recommendations on the roles of auto-HCT,
allo-HCT, and CAR T cell therapy in treating newly diagnosed
and R/R MCL. Considering the limitations of existing data on
treatments with cellular immunotherapy for MCL and the
recently approved CAR T cell therapy (brexucabtageneautoleucel) for R/R MCL [10], the optimal sequencing of
these treatments in the era of other novel therapies like
BTK inhibitors is unknown. Therefore, this undertaking was
conceived to provide a rational basis for clinical guidance
where evidence is limited, and it resulted in 17 consensus
recommendations.
Recommendations in the Front-Line Setting without TP53
Aberrations
Seven consensus statements were generated for transplan-
tation and CAR T cell treatments in the frontline setting for
MCL (Table 3). Taking into account the European MCL
Network randomized study for upfront auto-HCT consolida-
tion in MCL [4,13] and several other historical prospective tri-
als [18,24-26], the panel recommended auto-HCT as
consolidation therapy in eligible, newly diagnosed MCL
patients (without TP53 mutation or biallelic deletion) in com-
plete remission or partial remission after first-line therapies
(grade A recommendation; Table 3, recommendation 1).
Although this is in keeping with current guidelines [3], the
Consensus Panel did acknowledge that, owing to the lack of
evidence of a survival benefit with upfront auto-HCT consoli-
dation, some experts and centers do not routinely recommend
this modality after front-line intensive induction regimens. In
addition, the panel did not recommend auto-HCT as consolida-
tive therapy in MCL patients with disease refractory (or unre-
sponsive) to the most recent line of therapy (grade B
recommendation; Table 3, recommendation 2). Finally, given
the lack of prospective data to guide consolidative auto-HCT
based on the presence (or absence) of measurable residual dis-
ease (MRD), the panel did not recommend using MRD testing
to determine whether auto-HCT consolidation should be
applied, outside of a clinical trial (grade C recommendation;
Table 4
Final Clinical Practice Guidelines Consensus Statements for Transplantation and CAR T Cell Treatments for R/R MCL
Consensus Statement Grading of Recommendation* Panelists in Agreement, %
1. If a TP53 mutation (or biallelic deletion) is present, the panel does not recommend autolo-
gous transplantation in relapsed MCL patients achieving a complete or partial remission after
second or subsequent lines of therapy.
B 100
2. The panel recommends both CAR T cell therapy or allogeneic transplant consolidation as
acceptable options, in relapsed MCL patients with TP53 mutation (or biallelic deletion) in a
complete or partial remission after second or subsequent lines of therapy.
C 84.9
3. If a TP53 mutation (or biallelic deletion) is present, the panel recommends treatment with
CAR T cells in relapsed MCL patients, with disease unresponsive to last antilymphoma therapy.
B 97
4. In relapsed MCL patients, the panel recommends offering CAR T cell therapy before proceed-
ing with allogeneic transplantation.
C 81.8
5. Regarding timing of CAR T cell application in relapsed MCL patients (without TP53 mutation
or biallelic deletion), the panel recommends offering CAR T cell therapy to patients relapsing
after (or who are intolerant to) at least one BTK inhibitor.
B 93.9
6. The panel does not recommend allogeneic transplantation in relapsed MCL patients with dis-
ease refractory to most recent antilymphoma treatment.
B 93.9
7 The panel recommends allogeneic transplantation for eligible relapsed MCL patients who
have achieved only a partial remission with a BTK inhibitor in second or subsequent treatment
line, particularly in regions without access to CAR T cell therapy or in subjects where such ther-
apy is not feasible.
B 84.9
8. The panel recommends allogeneic transplantation in eligible MCL patients relapsing/pro-
gressing after CAR T cell therapy, if they achieve a complete or partial remission or if they have
stable disease with subsequent antilymphoma therapies.
C 84.9
9. Among eligible MCL patients lacking a TP53 mutation (or biallelic deletion) not undergoing
autologous transplant consolidation following first-line therapies, the panel recommends con-
sidering autologous transplantation consolidation therapy in patients who have achieved a
complete remission after second-line chemoimmunotherapies.
B 97
10. The panel recommends considering allogeneic transplant consolidation in eligible MCL
patients who still have detectable disease at 3 or more months following CAR T cell therapy.
C 100
* Agency of Healthcare Research and Quality grading of recommendations based on level of evidence [15]:
A: There is good research-based evidence to support the recommendation.
B: There is fair research-based evidence to support the recommendation.
C: The recommendation is based on expert opinion and panel consensus.
X: There is evidence of harm from this intervention.
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edge gap, the ongoing US Intergroup phase III study (ECOG-
ACRIN 4151; NCT03267433) is randomizing MRD-negative
MCL patients to undergo auto-HCT, followed by maintenance
rituximab or maintenance rituximab alone.
The Consensus Panel was not able to reach a consensus on
recommending the collection and storage of peripheral blood
hematopoietic progenitor cells (HPCs) for patients not under-
going upfront auto-HCT (Supplementary Tables S2 and S3).
The costs of collecting and storing HPCs for future use [27], as
well as ambiguity about the role of auto-HCT in the R/R setting
in the CAR T cell therapy era, were among the major concerns
raised by the panel. In addition, it was felt that if necessary,
peripheral blood HPC collection is feasible at a later point in
the disease process. Although a number of prognostic factors
can be used to predict outcomes for MCL, including the MCL
International Prognostic Index (MIPI) score [24,28,29], owing
to a lack of supporting data, the Consensus Panel did not rec-
ommend using the MIPI prognostic score as a criterion for
selecting patients for auto-HCT as consolidation therapy (grade
C recommendation; Table 3, recommendation 4).
Although the Consensus Panel anticipates that future trials
will investigate the role of CAR T cell therapies as consolidation
following frontline treatment, it does not recommend this
approach outside the setting of a clinical trial (grade C recom-
mendation; Table 3, recommendation 6).
Recommendations in the Front-Line Setting with TP53
Aberrations
The Consensus Panel recognized that that outcomes of MCL
patients with a TP53 mutation (or biallelic deletion) who are incomplete or partial remission after first-line treatments are
poor following auto-HCT consolidation [6]. Although there is
preliminary evidence that both allo-HCT and CAR T cell thera-
pies may overcome any treatment resistance conferred by TP53
aberrations [10,30], no alternative strategies have been shown
to improve the outcomes of first-line therapy in such patients in
a randomized trial. Therefore, the panel cautiously recom-
mended considering auto-HCT consolidation as well as other
alternative consolidation strategies (eg, CAR T cell therapy, allo-
HCT) for such patients, ideally in the context of a clinical trial
(grade C recommendation; Table 3, recommendation 7).
Recommendations in the R/R Setting
The Consensus Panel acknowledges that in the modern era
of novel immunotherapies, auto-HCT likely will have a limited
role in the management of R/R MCL, particularly in the pres-
ence of TP53 aberrations, where the panel does not recom-
mend auto-HCT (grade B recommendation; Table 4,
recommendation 1). However, among standard-risk MCL
patients (eg, those lacking a TP53 mutation or biallelic dele-
tion) not having undergone auto-HCT in first remission, the
panel felt that considering HDT consolidation therapy in the
subset of patients who have achieved complete remission after
second-line chemoimmunotherapy, particularly after a long
first remission, is reasonable and supported by observations in
more recent registry and other retrospective studies (grade B
recommendation; Table 4, recommendation 9) [12].
Brexucabtagene autoleucel was approved by the US Food
and Drug Administration (FDA) for treating R/R MCL on July
24, 2020, before the first voting survey. The Consensus Panel
felt that the FDA label did not identify the optimal timing of
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modality and the availability of other active targeted therapy
options, the panel recommended that CAR T cell therapy is
best applied in R/R MCL patients who are intolerant to or
relapsed after treatment with at least one BTK inhibitor (grade
B recommendation; Table 4, recommendation 5). This appears
to be in accordance with the European label for brexucabta-
gene autoleucel granted by the European Medicines Agency
(EMA) in December 2020 (after completion of this consensus
project) approving this CAR T cell therapy for R/R MCL after 2
lines of systemic therapy including a BTK inhibitor. However,
owing to the preliminary evidence of activity of CAR T cell
therapy in patients with a TP53 mutation [10], the use of CAR T
cell therapy as a second-line therapy (ie, even without prior
BTK inhibitor exposure) may be considered for such patients
(grade B recommendation; Table 4, recommendation 3).
With the approval of CAR T cell therapy for R/R MCL, the
role of allo-HCT merits reevaluation. The Consensus Panel rec-
ognizes the increased toxicities and life-threatening complica-
tions of allo-HCT and thus recommends considering CAR T cell
treatments before allo-HCT. In practical terms and taking into
account recommendation 5 (Table 4) for R/R disease, this
means that the treatment sequence would be to treat with
BTK inhibitors until failure or intolerance, then move to CAR T
cell therapy, and reserve allo-HCT for CAR T cell therapy fail-
ure. However, given the lack of comparative data of CAR T cell
therapy versus allo-HCT, the panel acknowledges that this rec-
ommendation represents an expert opinion for clinicians to
consider (grade C recommendation, Table 4, recommendation
4). Thus, allo-HCT remains an option as part of second-line
treatment in eligible patients who achieve only a partial
response to BTK inhibitors (ie, the majority of BTK inhibitor
responders [9,31]), particularly in areas where CAR T cell ther-
apies are not available (grade B recommendation; Table 4, rec-
ommendation 7).
In addition, the Consensus Panel considered allo-HCT to be
a reasonable treatment option in R/R MCL patients who have
relapsed after CAR T cell therapy, particularly if the disease
remains sensitive to subsequent treatment attempts (grade C
recommendation; Table 4, recommendation 8) [16,17,32-34].
This recommendation also can be considered for those patients
with persistent yet not progressive disease detectable beyond
3 months after CAR T cell administration (grade C recommen-
dation; Table 4, recommendation 10), taking into account the
low probability of durable disease control in this subset [10].
CONCLUSIONS
In clinical scenarios in which data from prospective studies
are either scarce or unavailable, or in situations where thera-
peutic advances or new drug indications make patient popula-
tions included in published trials less relevant to contemporary
clinical practice, formal consensus recommendations can be an
invaluable resource in informing clinical decision making [35].
Expert opinions and recommendations in the form of review
articles and treatment guidelines, although useful, lack method-
ological clarity and may be subject to bias [35]. In contrast, the
formulation of expert recommendations using established
approaches, such as the RAND-modified Delphi method [20],
provides a formal, reproducible, and systematic process.
With the rapidly changing landscape of therapeutic advan-
ces in cellular immunotherapies for MCL, the timing, sequence,
and feasibility of these novel therapies represent challenges.
We envision that clinical trials using CAR T cell therapies
potentially in earlier lines of treatment or in combination with
BTK inhibitors, may emerge. As a result, treatment algorithmsfor this disease are likely to continue to evolve. We hope that
these clinical practice recommendations will serve as a tool to
guide clinicians managing patients with newly diagnosed and
R/R MCL.
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